You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Amid the COVID-19 crisis, the global market for Nasal Drug Delivery Technology estimated at US$51.6 Billion in the year 2020, is projected to reach a revised size of US$73.3 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Nasal Sprays, one of the segments analyzed in the report, is projected to record a 6.2% CAGR and reach US$40 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Drops & Liquids segment is readjusted to a revised 4.4% CAGR for the next 7-year period. Read the full report: https://www.reportlinker.com/p05799205/?utm_source=PRN The U.S. Market is Estimated at $15.2 Billion, While China is Forecast to Grow at 4.8% CAGR The Nasal Drug Delivery Technology market in the U.S. is estimated at US$15.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.9 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR. Other Dosage Forms Segment to Record 2.5% CAGR In the global Other Dosage Forms segment, USA, Canada, Japan, China and Europe will drive the 2.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$4.2 Billion in the year 2020 will reach a projected size of US$5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.4 Billion by the year 2027.We bring years of research experience to this 7th edition of our report. The 278-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, 3M Company Aegis Therapeutics LLC Aptargroup, Inc. AstraZeneca PLC GlaxoSmithKline PLC Johnson & Johnson Merck & Co., Inc. Novartis International AG Pfizer, Inc. Read the full report: https://www.reportlinker.com/p05799205/?utm_source=PRN I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Global Competitor Market Shares Nasal Drug Delivery Technology Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Nasal Drug Delivery Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 2: World Historic Review for Nasal Drug Delivery Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 3: World 15-Year Perspective for Nasal Drug Delivery Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Nasal Sprays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 5: World Historic Review for Nasal Sprays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 6: World 15-Year Perspective for Nasal Sprays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Drops & Liquids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 8: World Historic Review for Drops & Liquids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 9: World 15-Year Perspective for Drops & Liquids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 11: World Historic Review for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 12: World 15-Year Perspective for Other Dosage Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Multi-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 14: World Historic Review for Multi-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 15: World 15-Year Perspective for Multi-dose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Unit-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 17: World Historic Review for Unit-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 18: World 15-Year Perspective for Unit-dose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Bi-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 20: World Historic Review for Bi-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 21: World 15-Year Perspective for Bi-dose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Allergic & Non-allergic Rhinitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 23: World Historic Review for Allergic & Non-allergic Rhinitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 24: World 15-Year Perspective for Allergic & Non-allergic Rhinitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 25: World Current & Future Analysis for Nose Congestion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 26: World Historic Review for Nose Congestion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 27: World 15-Year Perspective for Nose Congestion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 28: World Current & Future Analysis for Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 29: World Historic Review for Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 30: World 15-Year Perspective for Vaccination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 31: World Current & Future Analysis for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 32: World Historic Review for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 33: World 15-Year Perspective for Other Therapeutic Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 34: World Current & Future Analysis for Home Care Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 35: World Historic Review for Home Care Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 36: World 15-Year Perspective for Home Care Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 37: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 38: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 39: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Nasal Drug Delivery Technology Market Share (in %) by Company: 2019 & 2025 Market Analytics Table 40: USA Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 41: USA Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 42: USA 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027 Table 43: USA Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 44: USA Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 45: USA 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027 Table 46: USA Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 47: USA Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 48: USA 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027 Table 49: USA Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 50: USA Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 51: USA 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027 CANADA Table 52: Canada Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 53: Canada Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 54: Canada 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027 Table 55: Canada Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 56: Canada Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 57: Canada 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027 Table 58: Canada Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 59: Canada Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 60: Canada 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027 Table 61: Canada Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 62: Canada Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 63: Canada 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027 JAPAN Table 64: Japan Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 65: Japan Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 66: Japan 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027 Table 67: Japan Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 68: Japan Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 69: Japan 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027 Table 70: Japan Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 71: Japan Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 72: Japan 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027 Table 73: Japan Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 74: Japan Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 75: Japan 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027 CHINA Table 76: China Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 77: China Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 78: China 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027 Table 79: China Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 80: China Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 81: China 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027 Table 82: China Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 83: China Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 84: China 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027 Table 85: China Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 86: China Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 87: China 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027 EUROPE Market Facts & Figures European Nasal Drug Delivery Technology Market: Competitor Market Share Scenario (in %) for 2019 & 2025 Market Analytics Table 88: Europe Current & Future Analysis for Nasal Drug Delivery Technology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 89: Europe Historic Review for Nasal Drug Delivery Technology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 90: Europe 15-Year Perspective for Nasal Drug Delivery Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 91: Europe Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 92: Europe Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 93: Europe 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027 Table 94: Europe Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 95: Europe Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 96: Europe 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027 Table 97: Europe Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 98: Europe Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 99: Europe 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027 Table 100: Europe Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 101: Europe Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 102: Europe 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027 FRANCE Table 103: France Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 104: France Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 105: France 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027 Table 106: France Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 107: France Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 108: France 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027 Table 109: France Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 110: France Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 111: France 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027 Table 112: France Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 113: France Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 114: France 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027 GERMANY Table 115: Germany Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 116: Germany Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 117: Germany 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027 Table 118: Germany Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 119: Germany Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 120: Germany 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027 Table 121: Germany Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 122: Germany Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 123: Germany 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027 Table 124: Germany Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 125: Germany Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 126: Germany 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027 ITALY Table 127: Italy Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 128: Italy Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 129: Italy 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027 Table 130: Italy Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 131: Italy Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 132: Italy 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027 Table 133: Italy Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 134: Italy Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 135: Italy 15-Year Perspective for Nasal Drug Delivery Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p05799205/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001 SOURCE Reportlinker Related Links www.reportlinker.com

Answer: Global Nasal Drug Delivery Technology Industry Global Nasal Drug Delivery Technology Market to Reach $73.3 Billion by 2027